Antiangiogénicos en las oclusiones venosas retinianas

Caridad Chiang Rodríguez; Armando Ángel Chirino Chiang; Iraisi F. Hormigó Puertas; Leandro Peña Parra; Ariadna Corral Martín

Autores/as

Caridad Chiang Rodríguez Instituto Cubano de Oftalmología “Ramón Pando Ferrer”. La Habana, Cuba. https://orcid.org/0000-0001-9994-4201
Armando Ángel Chirino Chiang Instituto Cubano de Oftalmología “Ramón Pando Ferrer”. La Habana, Cuba. https://orcid.org/0000-0002-1188-1654
Iraisi F. Hormigó Puertas Instituto Cubano de Oftalmología “Ramón Pando Ferrer”. La Habana, Cuba. https://orcid.org/0000-0002-1099-8682
Leandro Peña Parra Instituto Cubano de Oftalmología “Ramón Pando Ferrer”. La Habana, Cuba.
Ariadna Corral Martín Universidad de Ciencias Médicas de las Fuerzas Armadas Revolucionarias. La Habana, Cuba. https://orcid.org/0000-0001-9439-8707

Palabras clave:

oclusión venosa retiniana; factores de riesgo; antiangiogénicos; inyecciones intravítreas; oclusión venosa de rama retiniana; oclusión venosa hemiretiniana; antiangiogénicos; vitrectomía pars plana; fotocoagulación; oclusión de vena central de la retina.

Resumen

La oclusión venosa retiniana constituye la segunda causa más frecuente de enfermedad vascular retiniana, después de la retinopatía diabética; provoca la afectación visual y un alto índice de costos por sus complicaciones. Múltiples estudios epidemiológicos internacionales relevantes estiman una prevalencia global de la enfermedad en 28,06 millones de personas en 2015 y una tendencia al incremento en el período 2020-2030. Las opciones terapéuticas aplicadas en el edema macular y la isquemia retinal como complicaciones de la enfermedad oclusiva venosa retiniana son diversas. Se realizó una revisión de la literatura científica para valorar la eficacia y seguridad del uso de los antiangiogénicos intravítreos como primera línea en el tratamiento del edema macular por oclusión venosa retiniana. Se demostró que se lograba una significativa recuperación de la estructura y función en la oclusión venosa retiniana con inyecciones de antiangiogénicos repetidas, que producen escasos efectos adversos.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

1. Arepalli S, Bessette A, Kaiser K. Branch Retinal Vein Occlusion. En: Sadda S, Schachat A, Wilkinson C, Hinton D, Wiedemann P, Freund K, Sarraf D, editors. Ryan’s RETINA. 7ma ed. US: Elsevier Inc.; 2022 [acceso 02/09/2025]:1177-88. Disponible en: https://shop.elsevier.com/books/ryans-retina/sadda/978-0-323-72213-1

2. Oellers P, Oellers P, Hahn P, Ip M, Fekrat S. Central Retina Vein Occlusion. En: Sadda S, Schachat A, Wilkinson C, Hinton D, Wiedemann P, Freund K, Sarraf D, editors. Ryan’s RETINA. 7ma ed. US: Elsevier Inc.; 2022 [acceso: 02/09/2025]:1189-204. Disponible en: https://shop.elsevier.com/books/ryans-retina/sadda/978-0-323-72213-1

3. Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global Epidemiology of Retinal Vein Occlusion: A Systematic Review and Meta-Analysis of Prevalence, Incidence, and Risk Factors. J Global Health. 2019;9(1):1-10:010427. DOI: https://doi.org/10.7189/jogh.09.010427

4. Rogers S, McIntosh R, Cheung N, Lim L, Wang J, Mitchell P, et al. International Eye Disease Consortium. The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-9. DOI: https://doi.org/10.1016/j.ophtha.2009.07.017

5. Sivaprasad S, Nicholson L, Amoaku W, Talks J, Talks K. Retinal Vein Occlusion (RVO). Londres. Consultation Document. The Royal College of Ophthalmologists. Clinical Guidelines. 2022 [acceso 02/09/2025]. Disponible en: https://www.rcophth.ac.uk/wp-content/uploads/2015/07/Retinal-Vein-Occlusion-Guidelines-2022.pdf

6. Nicholson L, Vázquez-Alfageme C, Sen P, Patrao N, Peto T, Yang Y, et al. The Clinical Relevance of Ultra-Widefield Angiography Findings in Patients with Central Retinal Vein Occlusion and Macular Oedema Receiving Anti-VEGF Therapy. Eye. 2022;36(5):1086-93. DOI: https://doi.org/10.1038/s41433-021-01553-7

7. Haydinger C, Ferreira L, Williams K, Smith J. Mechanisms of Macular Edema. Front. Med. 2023;10:1128811. DOI: https://doi.org/10.3389/fmed.2023.1128811

8. Kovach J, Bailey S, Kim S, Lim J, Vemulakonda G, Ying G, et al. American Academy of Ophthalmology Preferred Practice Pattern Retina/Vitreous Committee. Retinal Vein Occlusions Preferred Practice Pattern®. Ophthalmology. 2025;132(4):P303-P343. DOI: https://doi.org/10.1016/j.ophtha.2024.12.025

9. Hattenbach L, Abreu F, Arrisi P, Basu K, Danzig C, Guymer R, et al. BALATON and COMINO: Phase III Randomized Clinical Trials of faricimab for Retinal Vein Occlusion: Study Design and Rationale. Ophthalmol Sci.2023;3(3):100302. DOI: https://doi.org/10.1016/j.xops.2023.100302

10. Brown D, Campochiaro P, Bhisitkul R, Ho A, Gray S, Saroj N, et al. Sustained Benefits from ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12. Month Outcomes of a Phase III Study. Ophthalmology. 2011;118(8):1594-602. DOI: https://doi.org/10.1016/j.ophtha.2011.02.022.

11. Campochiaro P, Brown D, Awh, Lee S, Gray S, Saroj N, et al for the CRUISE Investigators. Sustained Benefits from Ranibizumab for Macular Edema Following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase Iii Study. Ophthalmology. 2011;118(10):2041-49. DOI: https://doi.org/10.1016/j.ophtha.2011.02.038

12. Heier J, Campochiaro P, Yau L, Li Z, Saroj N, Rubio R, Lai P. Ranibizumab for Macular Edema Due to Retinal Vein Occlusion: Long-Term Follow-Up in the HORIZON Trial. Ophthalmology. 2012;119(4):802-9. DOI: https://doi.org/10.1016/j.ophtha.2011.12.005

13. Campochiaro P, Sophie R, Pearlman J, Brown D, Boyer D, Heier J, et al. RETAIN Study Group. Long-Term Outcomes in Patients with Retinal Vein Occlusion Treated with ranibizumab: The RETAIN Study. Ophthalmology. 2014;121(1):209-19. DOI: https://doi.org/10.1016/j.ophtha.2013.08.038

14. Campochiaro P, Wykoff C, Singer M, Johnson R, Marcus D, Yau L, et al. Monthly versus As-Needed Ranibizumab Injections in Patients with Retinal Vein Occlusion: The SHORE Study. Ophthalmology. 2014;121(12):2432-42. DOI: https://doi.org/10.1016/j.ophtha.2014.06.011.

15. Heier J, Clark W, Boyer D, Brown D, Vitti R, Berliner A et al. Intravitreal Aflibercept Injection for Macular Edema Due To Central Retinal Vein Occlusion: Two-Year Results from the COPERNICUS Study. Ophthalmology. 2014;121(7):1414-20. DOI: https://doi.org/10.1016/j.ophtha.2014.01.027.

16. Ogura Y, Roider J, Korobelnik J, Holz F, Simader C, Schmidt-Erfurth U, et al. GALILEO Study Group. Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO study. Am J Ophthalmol. 2014;158(5):1032-8. DOI: https://doi.org/10.1016/j.ajo.2014.07.027.

17. Clark W, Boyer D, Heier J, Brown D, Haller J, Vitti R et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology. 2016;123(2):330-6. DOI: https://doi.org/10.1016/j.ophtha.2015.09.035.

18. Narayanan R, Stewart M, Chhablani J, Panchal B, Pappuru R, Das T et al. Baseline Morphological Characteristics as Predictors of Final Visual Acuity in Patients with Branch Retinal Vein Occlusions: MARVEL report no. 3. Indian J Ophthalmol. 2018;66(9):1291-4. DOI: https://doi.org/10.4103/ijo.IJO_342_18

19. Campochiaro P, Hafiz G, Mir T, Scott A, Solomon S, Zimmer-Galler et al. Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial. Ophthalmology. 2015;122(7):1426-37. DOI: https://doi.org/10.1016/j.ophtha.2015.04.006.

20. Larsen M, Waldstein S, Priglinger S, Hykin P, Barnes E, Gekkieva M et al CRYSTAL Study Group. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study. Ophthalmol Retina. 2018;2(2):134-42. DOI: https://doi.org/10.1016/j.oret.2017.05.016.

21. Tadayoni R, Waldstein S, Boscia F, Gerding H, Gekkieva M, Barnes E, The BRIGHTER study group. Sustained Benefit of Ranibizumab with or without Laser in Branch Retinal Vein Occlusion: 24-month results of BRIGHTER. Ophthalmology. 2017;124(12):1778-87. DOI: https://doi.org/10.1016/j.ophtha.2017.06.027

22. Scott I, Van P, Oden N, Ip M, Blodi B, The SCORE2 Investigator Group. Month 60 Outcomes After Treatment Initiation with Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion. Am J Ophthalmol. 2022; 240:330-41. DOI: https://doi.org/10.1016/j.ajo.2022.04.001

23. Callizo J, Ziemssen F, Bertelmann T, Feltgen N, Vögeler J, Koch M, et al. Real-World Data: Ranibizumab Treatment for Retinal Vein Occlusion in The OCEAN Study. Clin Ophthalmol. 2019;13: 2167-79. DOI: https://doi.org/10.2147/OPTH.S209253

24. Hykin P, Prevost T, Vasconcelos J, Murphy C, Kelly J, Ramu J, et al; for the LEAVO Study Group. Clinical Effectiveness of Intravitreal Therapy with Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion. A Randomized Clinical Trial. JAMAOphthalmol. 2019;137(11):1256-64. DOI: https://doi.org/10.1001/jamaophthalmol.2019.3305

25. Pearce I, Clemens A, Brent M, Lu L, Gallego-Pinazo R, Minnella A, all the LUMINOUS study investigators. Real-world Outcomes with Ranibizumab in Branch Retinal Vein Occlusion: The Prospective, Global, LUMINOUS Study. PLoS ONE. 2020; 15(6):1-13,e 0234739. DOI: https://doi.org/10.1371/journal.pone.0234739.

26. Sharma S, Khan M, Chaturvedi A, RE-ENACT Study Investigators Group. A Multicenter, Retrospective Study (RE-ENACT2) on RazumabTM (World’s First Biosimilar Ranibizumab) in Retinal Vein Occlusion. Ophthalmol Ther. 2020;9(3):625-39. DOI: https://doi.org/10.1007/s40123-020-00277-3

27. Korobelnik J, Larsen M, Eter N, Bailey C, Wolf S, Schmelter T et al. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: The CENTERA Study. Am J Ophthalmol. 2021;227:106-15. DOI: https://doi.org/10.1016/j.ajo.2021.01.027.

28. Ghanchi F, Abreu F, Arrisi P, Kotecha A, Liu Y, Paris LP, et al. Efficacy, safety, and durability of faricimab in macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials. IOVS. 2024 [acceso 02/12/2025];65(7):3124. Disponible en: https://iovs.arvojournals.org/article.aspx?articleid=2798271

29. Danzig C, Dinah C, Ghanchi F, Hattenbach L, Khanani A, Lai T, BALATON and COMINO Investigators. Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials. Ophthalmology Retina. 2025;9(9):848-59. DOI: https://doi.org/10.1016/j.oret.2025.03.005

30. Zoco G. Controversias, Estado Actual y Perspectivas del Tratamiento de las Oclusiones Vasculares Venosas de la Retina. Fac. Med. Enf. TTR Medicina; 2021.

31. Spooner K, Fraser-Bell S, Hong T, Wong J, Chang A. Long-term outcomes of anti-VEGF treatment of retinal vein occlusion. Eye. 2022;36(6):1194-201. DOI: https://doi.org/10.1038/s41433-021-01620-z

32. Nicholson L, Talks S, Amoaku W, Talks K, Sivaprasad S. The Royal College of Ophthalmologists 2022. Retinal vein occlusion (RVO) guideline: executive summary. Eye. 2022; 36(5):909-12. DOI: https://doi.org/10.1038/s41433-022-02007-4

33. Rapuano C, Stout J, McCannel C. Retinal Vascular Diseases Associated with Cardiovascular Disease. En: Kim S, Fawzi A, Kovach J, Patel S, Rechia F, Sobrin L, et al, editors. Retina and Vitreous. Basic and Clinical Science Course (BCSC). 12 ed. US: AAO; 2023-2024. p.131-166.

34. Romano F, Lamanna F, Gabrielle P, Teo K, Battaglia P, Iacono P et al. Update on Retinal Vein Occlusion. Asia Pac J Ophthalmol (Phila). 2023;12(2):196-210. DOI: https://doi.org/10.1097/APO.0000000000000598

35. Valverde-Urrea M. Noticias en Terapéutica: La FDA aprueba el uso del anticuerpo dual faricimab para tratar la oclusión venosa retiniana. Actualidad en Farmacología y Terapéutica (aft). 2023 [acceso 22/12/2025];21(4):306-7. Disponible en: https://observatorio-cientifico.ua.es/documentos/68963b9e7d435e37fc5fe434

Antiangiogénicos en las oclusiones venosas retinianas

Autores/as

Palabras clave:

Resumen

Descargas

Citas

Descargas

Publicado

Cómo citar

Número

Sección

Licencia

Idioma

Enviar un artículo

Crea tu Identificador ORCID

Información

Indexada en

Palabras clave

Publicación